Remzistotug Biosimilar Monoclonal Antibody (CD112R) for Research

Cat No.: GMP-Bios-INN-1362

Anti-PVRIG/NECTIN2 receptor/CD112R therapeutic antibody (Pre-made Remzistotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Remzistotug (development codes GSK4381562/SRF813) is a humanized monoclonal antibody targeting PVRIG. It is developed by GlaxoSmithKline for Neoplasms in Phase II development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1362-1mg 1mg 3090
GMP-Bios-INN-1362-10mg 10mg
GMP-Bios-INN-1362-100mg 100mg
GMP-Bios-INN-1362-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Remzistotug biosimilar, Whole mAb, Anti-PVRIG/NECTIN2 receptor/CD112R Antibody: Anti-PVRIG/Transmembrane protein PVRIG/CD112 receptor (CD112R)/Poliovirus receptor-related immunoglobulin domain-containing protein therapeutic antibody
INN Name Remzistotug
Target PVRIG/NECTIN2 receptor/CD112R
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC